Research Article
The Value of Tranexamic Acid in Reducing Blood Loss following Hip Reconstruction in Children with Cerebral Palsy
Table 3
Primary and secondary outcomes.
| | | No tranexamic acid | Tranexamic acid | (95% CI), |
| | Transfusion rate | 13/36 (36.1%) | 6/14 (42.9%) | 6.7% (−21.3% to 36.1%), | | Total blood loss, mL | 971 (SD 766) | 969 (SD 742) | −2 (−536 to 531), | | Postop Hb, g/dL | 9.4 (SD 1.76) | 8.9 (SD 1.5) | −0.5 (−1.7 to 0.7), | | Postop Hct | 0.29 (SD 0.06) | 0.27 (SD 0.04) | −0.02 (−0.06 to 0.02), | | Hb drop, g/dL | 4.1 (SD 1.9) | 4.3 (SD 2.0) | 0.2 (−1.1 to 1.6), | | Length of stay, days | 7.63 (SD 4.2) | 8.17 (SD 3.9) | 0.54 (−2.37 to 3.44), |
|
|
Hb: hemoglobin, Hct: hematocrit, and SD: standard deviation.
|
